After an FDA rejection, here’s what’s next in the psychedelics pipeline
PharmaVoice
AUGUST 28, 2024
By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.
Wed.Aug 28, 2024
336 
Drug Topics Top 10: Most Read Stories From August 2024
Drug Topics
AUGUST 28, 2024
Check out this list of our top 10 stories from August 2024.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
STAT+: UnitedHealth pledged a hands-off approach after buying a Connecticut medical group. Then it upended how doctors practice
STAT
AUGUST 28, 2024
MIDDLETOWN, Conn. — UnitedHealth Group told the Connecticut primary care doctors everything they wanted to hear. Take our money, the company said, and together we can bring about a future where primary care leads. A future where doctors can take better care of their patients, and reap the financial rewards of improved health. We’ll handle the business side while you look after your patients.
Inclisiran Monotherapy Significantly Reduces LDL-C in ASCVD
Drug Topics
AUGUST 28, 2024
Additional data will be presented at a scientific meeting later this year.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PQA Issues Call to Action to Improve Medication Therapy Management
Pharmacy Times
AUGUST 28, 2024
Eight areas of improvement were developed as part of national initiative with stakeholder involvement.
Investigational Acute Pain Therapy to be Evaluated in Pivotal Phase 3 Trials
Drug Topics
AUGUST 28, 2024
Tris Pharma will examine the efficacy and safety of cebranopadol in the ALLEVIATE-1 and ALLEVIATE-2 studies.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
ICYMI: Drug Topics July/August 2024 Issue
Drug Topics
AUGUST 28, 2024
Don’t miss out on the latest pharmacy insights in the Drug Topics July/August issue.
NIH launches $270 million anti-overdose research program for, and led by, Native Americans
STAT
AUGUST 28, 2024
Fatal drug overdoses shot up during the peak of Covid-19 in 2020. And as the dust settled on the pandemic, it quickly became clear that one demographic group had fared far worse than any other: Native Americans. Now, to combat the drug crisis and its disproportionate impact on indigenous people, the federal government is launching an initiative specifically meant to bolster research into addiction and overdose within native communities.
Activation, Preparedness Following Treatment Lacking Among Lymphoma Survivors
Pharmacy Times
AUGUST 28, 2024
In survivors of lymphoma with fragmented transition of care, preparedness and activation for the next phase of their survivorship was lacking.
STAT+: Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial
STAT
AUGUST 28, 2024
Neurocrine Biosciences said Wednesday that the lowest dose of an experimental pill for schizophrenia reduced psychosis reported by patients in a mid-stage study, but higher doses of the drug also tested were ineffective. The company said the study results supported advancing the medicine into Phase 3 studies next year. Investors viewed the mixed data with more concern, sending Neurocrine’s stock down 18% in early trading.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
FINTOX May Improve Financial Toxicity Screening in Cancer Treatment
Pharmacy Times
AUGUST 28, 2024
Accurate, effective screening is crucial for connecting patients with needed financial resources and support.
Opinion: Medicare’s new transitional coverage of emerging technologies program doesn’t go far enough
STAT
AUGUST 28, 2024
Included in the original law that established Medicare in 1965 was a short but consequential mandate that the program only pay for items and services that are “reasonable and necessary” for the treatment of illness and injury. Over the decades that followed, this requirement was generally viewed as excluding from coverage those medical services and products that were experimental or investigational, or for which there was still uncertainty about the benefits and harms for Medicare
FDA Grants Priory Review for Mirdametinib to Treat NF1-PN
Pharmacy Times
AUGUST 28, 2024
Mirdametinib is an oral, allosteric small molecule MEK inhibitor to treat pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Details emerge of £400m investment programme tied to VPAG
pharmaphorum
AUGUST 28, 2024
The £400m pledged by industry as part of the new VPAG voluntary scheme of pharma rebates will be used mainly to support the UK clinical research sector
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacists' Guide to Evolocumab for Lowering LDL-C
Pharmacy Times
AUGUST 28, 2024
Pharmacists can play a crucial role in educating patients on the proper storage and administration of evolocumab.
AI voice assistant can spot complications in heart patients
pharmaphorum
AUGUST 28, 2024
A virtual voice assistant used to contact patients after heart procedures can make early discharge possible and spot complications
We like to think UK health services aren’t influenced by big money. That’s just not true | Margaret McCartney
The Guardian - Pharmaceutical Industry
AUGUST 28, 2024
There must be transparency over funding to medics from the pharmaceutical industry – and that’s only the start Shouldn’t we be able to trust doctors to give us independent advice? Earlier this year, there was an outcry when it appeared that a doctor who often appeared on TV to speak about Covid vaccines had been paid a significant sum by the pharmaceutical company AstraZeneca.
Community Pharmacist Training Program Enhances Care for Patients With Epilepsy
Pharmacy Times
AUGUST 28, 2024
Community pharmacists can participate in continuing education epilepsy programs, but they are usually not specific to pharmacy practice.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Hims takes a blow from Lilly’s vial news
STAT
AUGUST 28, 2024
Good morning. As a treat for Labor Day weekend, we’re running a deal for STAT+ subscriptions. If you use the code LABORDAY at checkout, you can get 25% off your first year. Learn more here. Now onto the biotech news of the day.
Type 2 diabetes drug associated with 35% lower risk of dementia, study finds
The Guardian - Pharmaceutical Industry
AUGUST 28, 2024
Large Korean study suggests sodium-glucose cotransporter-2 inhibitors may prevent dementia A drug used to treat type 2 diabetes is associated with a 35% lower risk of dementia, according to research. The number of people with dementia globally is expected to nearly triple to 153 million by 2050. The health and social costs linked to dementia already exceed $1tn (£780bn) a year , research shows.
Novartis collaboration to innovate subcutaneous drug delivery
European Pharmaceutical Review
AUGUST 28, 2024
Novartis Pharma AG and biotech Lindy Biosciences have agreed to collaborate to advance subcutaneous biologic injectables. As part of a worldwide licensing agreement and collaboration, some of Novartis’ medicines will be developed into the injections via Lindy Biosciences’ proprietary microglassification suspension technology. This platform enables high concentrations of biologics to be delivered in a single dose, improving the convenience of administration and patient and treatment compliance, a
Our investigation of UnitedHealth, explainer on Oropouche and news on maternal health
STAT
AUGUST 28, 2024
Want to stay on top of health news? Sign up to get our Morning Rounds newsletter in your inbox. Good morning! Amid today’s news, two items on pregnancy that are interesting and eerie to read in tandem. And on top of that, two itchy pieces of mosquito-related news from STAT’s Helen Branswell.
HDA 2024 Traceability Seminar: DSCSA Implementation and Readiness
Pharmaceutical Commerce
AUGUST 28, 2024
Session uncovers distributors’ experiences with the Waiver, Exception, or Exemption request process, and how these affect the overall supply chain.
BioMarin cuts deeper with 225 layoffs under CEO's new corporate strategy
Fierce Pharma
AUGUST 28, 2024
The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech. | The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech.
STAT+: Pharmalittle: We’re reading about Zantac court cases, a Neurocrine schizophrenia pill, and more
STAT
AUGUST 28, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
Pharma Pulse 8/28/24: AI Regulation Is Coming, A Case for Payer Engagement/Participation in Clinical Research & more
Pharmaceutical Commerce
AUGUST 28, 2024
The latest news for pharma industry insiders.
Rivaroxaban Clinical Pearls – 4 Big Ones
Med Ed 101
AUGUST 28, 2024
Rivaroxaban is classified as a direct oral anticoagulant. It is one of the most commonly used anticoagulants within this class (in addition to apixaban). In this blog post, I’ll share the 5 most important rivaroxaban clinical pearls that may appear in practice or on a board exam! Dosing of Rivaroxaban There are a couple of […] The post Rivaroxaban Clinical Pearls – 4 Big Ones appeared first on Med Ed 101.
Changing Faces – Board of Directors appointments from July 2024
pharmaphorum
AUGUST 28, 2024
Changing Faces announces new board of directors appointments from July 2024 for Immatics, Memo Therapeutics, Scancell, Abcuro and more. Stay updated on the latest developments in the biotech industry.
Novartis taps Lindy to turn biologic drugs into at-home injectables, puts nearly $1B on the line
Fierce Pharma
AUGUST 28, 2024
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. | Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.
Lilly launches single-dose Zepbound to ease self-pay access
pharmaphorum
AUGUST 28, 2024
Lilly launches single-dose Zepbound to ease self-pay access Phil.
HHS Releases Campaign to Promote Vaccine Recommendations for RSV, COVID-19, and Flu
Pharmacy Times
AUGUST 28, 2024
"Risk Less. Do More." plans to partner with national, state, and local organizations to provide resources to families and communities on how to protect themselves from RSV, influenza, and COVID-19.
Novartis builds case for Leqvio with monotherapy data
pharmaphorum
AUGUST 28, 2024
Novartis builds case for fast-growing cholesterol drug Leqvio, as V-MONO trial shows benefit as a monotherapy in patients at lower risk of heart disease
In key win for GSK, Delaware court will review decision to allow expert testimony in Zantac cases
Fierce Pharma
AUGUST 28, 2024
Delaware's Supreme Court has upheld a GSK appeal, deciding to review the state’s Superior Court decision to allow expert testimony in Zantac lawsuits.
Let's personalize your content